Stock listing

OTC:BITRF Biotron Limited Stock

US listing (OTC) of Biotron Limited · home listing ASX:BIT

Follow Biotron Limited into a list and get an email when it puts out news.

Share price · OTC:BITRF

$0.0028 USD 0.0000 (0.0%)

Close on Nov 12, 2026

Past year +133.3% · daily closes, Nov 14, 2025 – Nov 12, 2026, adjusted for splits
Day range
$0.0028 – $0.0028 USDNov 12, 2026
52-week range
$0.0011 – $0.1014 USDLowest and highest trades, Nov 14, 2025 – Nov 12, 2026
Traded on an average day
$18 USDMedian day 0 shares · 50 days with no trades · last 3 months, Aug 19, 2026 – Nov 12, 2026
Biotron Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:BIT · Home$0.0020 AUD0.0000 (0.0%)1,019,027$0.0020$0.0020$0.0020$0.0020Close on Nov 20, 2026
OTC:BITRF$0.0028 USD0.0000 (0.0%)—$0.0028$0.0028$0.0028$0.0028Close on Nov 12, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 12, 2026 · OTC:BITRF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00280.00000.0%$0.0028$0.0028$0.00280
$0.0028+0.0013+86.7%$0.0028$0.0028$0.002820,000
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.0015+0.0002+15.4%$0.0015$0.0015$0.0015400,000
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.0013-0.0002-13.3%$0.0013$0.0013$0.0013110,000
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.00150.00000.0%$0.0015$0.0015$0.00150
$0.0015+0.0002+15.4%$0.0015$0.0015$0.0015100,000
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.001320,000
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.00130.00000.0%$0.0013$0.0013$0.00130
$0.0013-0.0007-35.0%$0.0400$0.0400$0.001340,000

Splits

2 splits since 2014 · OTC:BITRF · every price before a split is adjusted for it

DayRatioWhat
54-for-49Split
33-for-31Split
Ticker
OTC:BITRF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

Annual Report/Notice of AGM/Proxy Form

Oct 22, 2026

Closed $0.0015 (0.0%) on Oct 23, 2026

Appointment of CEO and Executive Director

Oct 13, 2026

Closed $0.0015 (0.0%) on Oct 14, 2026

Change of Share Registry

Sep 3, 2026

Closed $0.0013 (0.0%) on Sep 4, 2026

Investor Presentation

Sep 2, 2026

Closed $0.0013 (0.0%) on Sep 3, 2026

Appendix 4G

Aug 26, 2026

Closed $0.0013 (0.0%) on Aug 27, 2026

All Biotron Limited news

Biotron Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 98 in all · newest Nov 8, 2026 · oldest 2016
Decks
101 decks · latest Sep 3, 2026

Where Biotron Limited is listed

ListingExchangeCountryCurrency
ASX:BIT · Home listingASXAustraliaAUD
OTC:BITRF · This pageOTCUnited StatesUSD

Cash and shares

Sep 2026 deck · Biotron — Biotech Showcase, Melbourne (September 2026)

Shares outstanding
228 million

The slide these figures come from

Valuation

Price/book 1.9× against a median of 0.8×: 8th lowest of 11 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$4.02M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Biotron Limited · ASX:BITUS$3.69MUS$2.66Mn/an/an/a1.9×n/a0.0×n/a
AdAlta Ltd. · ASX:1ADUS$4.25MUS$3.40Mn/an/an/a17.4×n/a0.0×n/a
Percheron Therapeutics Limited · ASX:PERUS$3.94MUS$1.27Mn/an/an/a0.8×n/a0.0×n/a
Lantern Pharma Inc. · NASDAQ:LTRNUS$3.89M−US$3.69Mn/an/an/a2.8×n/a0.0×2.80
Silo Pharma, Inc. · NASDAQ:SILOUS$3.77M−US$4.28Mn/an/an/a0.5×n/a0.0×1.23
Alzamend Neuro, Inc. · NASDAQ:ALZNUS$3.74M−US$3.85Mn/an/an/a0.7×n/a0.0×2.00
Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPHUS$3.68M−US$13.77Mn/an/an/a0.3×n/a0.0×1.57
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.20MUS$22,063n/a5.6×n/a1.0×n/a0.0×n/a
Median of the othersUS$3.71M−US$3.11M2.4×0.8×−123.7%0.0×1.46

Team and board

Officers

OfficerRole
Marcelo MoraCompany Secretary

Board

DirectorRole
Paul KasianIndependent and Non-Executive Chairman
Graeme WaldIndependent and Non-Executive Director
Michael J. ThurnIndependent and Non-Executive Director
Michael MedwayIndependent and Non-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 27, 2025+33.3%
Q2 2025Feb 28, 2025−55.6%
Q2 2023Feb 17, 2023 · After close0.0%
Q4 2022Aug 19, 2022 · After close−1.6%
Q2 2022Feb 23, 2022−3.2%
Q4 2021Aug 27, 20210.0%
Q2 2021Feb 23, 2021−6.7%

Open Events

Decks

DeckKindSlidesDate
Biotech Showcase, Melbourne (September 2026)Conference12 slidesSep 3, 2026
Investor Presentation (November 2025)Investor deck32 slidesNov 11, 2025
Investor Presentation (October 2025)Investor deck15 slidesOct 15, 2025
Shareholder Meeting (November 2024)Shareholder meeting20 slidesNov 28, 2024
Shareholder Meeting (November 2024)Shareholder meeting17 slidesNov 28, 2024
Investor Presentation (June 2024)Investor deck12 slidesJun 26, 2024
Shareholder Meeting (November 2023)Shareholder meeting14 slidesNov 22, 2023
Shareholder Meeting (November 2023)Shareholder meeting12 slidesNov 22, 2023
Investor Presentation (October 2023)Investor deck14 slidesOct 24, 2023
Investor Presentation (October 2023)Investor deck13 slidesOctober 2023
Show 50 decks
DeckKindSlidesDate
Shareholder Meeting (November 2022)Shareholder meeting13 slidesNov 16, 2022
Investor Presentation (November 2022)Investor deck13 slidesNov 11, 2022
Investor Presentation (November 2022)Investor deck12 slidesNovember 2022
Investor Presentation (November 2021)Investor deck17 slidesNov 25, 2021
Shareholder Meeting (November 2021)Shareholder meeting16 slidesNov 23, 2021
Shareholder Meeting (November 2021)Shareholder meeting13 slidesNov 23, 2021
Investor Presentation (October 2021)Investor deck13 slidesOctober 2021
Shareholder Meeting (November 2020)Shareholder meeting15 slidesNov 19, 2020
Shareholder Meeting (November 2020)Shareholder meeting14 slidesNov 19, 2020
Investor Presentation (October 2020)Investor deck11 slidesOct 14, 2020
Investor Presentation (October 2020)Investor deck10 slidesOctober 2020
Shareholder Meeting (November 2019)Shareholder meeting22 slidesNov 26, 2019
Shareholder Meeting (November 2019)Shareholder meeting19 slidesNov 26, 2019
Australia Biotech Invest and Partnering 2019Conference13 slidesOct 31, 2019
2019 BIO International ConventionConference15 slidesJun 7, 2019
BIO 2019Conference13 slidesJune 2019
Shareholder Meeting (November 2018)Shareholder meeting22 slidesNov 20, 2018
Shareholder Meeting (November 2018)Shareholder meeting19 slidesNovember 2018
Investor Presentation (October 2018)Investor deck17 slidesOct 25, 2018
Biotech Showcase 2018Conference22 slidesJanuary 2018
Shareholder Meeting (November 2017)Shareholder meeting19 slidesNov 20, 2017
Shareholder Meeting (November 2017)Shareholder meeting16 slidesNov 20, 2017
Investor Presentation (October 2017)Investor deck15 slidesOct 6, 2017
Biotech Showcase 2017Conference26 slidesJan 13, 2017
Biotech Showcase 2017Conference21 slidesJanuary 2017
Biotech Showcase 2017Conference25 slidesJanuary 2017
Shareholder Meeting (November 2016)Shareholder meeting22 slidesNov 22, 2016
Shareholder Meeting (November 2016)Shareholder meeting19 slidesNov 22, 2016
Biotech Invest 2016Conference12 slidesMay 4, 2016
Singapore Biotech Invest 2016 / Asia Biotech Invest 2016Conference11 slidesMay 2016
Biotech Showcase 2016Conference21 slidesJanuary 2016
Shareholder Meeting (November 2015)Shareholder meeting16 slidesNov 24, 2015
Shareholder Meeting (November 2015)Shareholder meeting13 slidesNov 24, 2015
Investor Presentation (October 2015)Investor deck10 slidesOct 6, 2015
Australia Biotech Invest 2015Conference9 slidesOctober 2015
Investor Presentation (August 2015)Investor deck14 slidesAug 20, 2015
Investor Presentation (May 2015)Investor deck11 slidesMay 28, 2015
Broker Meets Biotech 2015Conference10 slidesMay 2015
Biotech Showcase 2015Conference21 slidesJanuary 2015
Investor Presentation (December 2014)Investor deck17 slidesDec 4, 2014

This page holds 50 of 101 decks. Open Decks

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue1.81M1.65M1.43M1.56M1.46M803.0K1.07M1.62M1.66M
Cost of revenue1.91K11.1K40.5K43.3K45.3K47.3K50.1K12.5K11.6K13.1K
Gross profit-1.91K1.81M1.65M1.39M1.51M1.41M752.9K1.06M1.61M1.65M
Research and development683.3K535.4K3.62M3.23M2.82M3.14M2.86M1.12M1.69M3.16M
Selling, general and administrative1.24M769.3K528.5K696.7K228.0K228.0K237.2K299.6K275.7K242.0K
Operating income-1.93M-338.8K-5.15M-5.04M-2.78M-4.32M-4.05M-2.77M-1.61M-4.40M
Depreciation and amortization1.91K11.1K40.5K43.3K45.3K47.3K50.1K12.5K11.6K13.1K
EBITDA-1.93M-327.6K-5.11M-5.00M-2.73M-4.27M-4.00M-2.76M-1.60M-4.38M
Interest expense14.6K1.09K4.39K5.05K1.26K5.12K5.12K00
Income before tax-2.04M-318.6K-3.44M-4.92M-2.78M-4.61M-4.33M-2.68M-1.59M-4.71M
Income tax-525.9K-1.81M-1.65M-1.43M5-1.41M-753.0K-1.07M-1.62M-1.61M
Net income-1.52M-318.6K-3.44M-3.49M-2.78M-3.19M-3.58M-1.61M-1.59M-3.09M
Earnings per share, basic-0.00-0.00-0.00-0.00-0.00-0.00-0.01-0.00-0.00-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents1.55M931.7K393.2K3.98M1.74M4.21M7.66M5.74M1.54M1.99M
Short-term investments00
Receivables18.0K7.08K18.2K23.1K
Inventory811
Current assets1.59M955.4K426.8K4.03M1.76M4.26M7.72M5.78M1.60M2.03M
Property, plant and equipment4.59K12.6K49.9K89.7K30.9K73.2K46.3K17.9K29.5K
Total assets3.74M980.4K493.5K4.14M1.91M4.33M7.83M5.86M1.62M2.06M
Accounts payable50.6K89.9K285.5K285.2K310.9K138.2K310.0K158.3K135.8K344.2K
Current liabilities817.9K428.5K737.5K955.8K750.6K451.2K840.8K412.1K337.7K619.5K
Total debt7.13K45.3K77.2K6.35K44.0K44.0K
Total liabilities817.9K428.5K737.5K962.5K813.6K463.5K853.2K418.0K337.7K619.5K
Shareholders' equity2.92M551.9K-244.0K3.17M1.09M3.86M6.97M5.44M1.28M1.44M
Shares outstanding2.07B999.2M902.2M820.8M724.8M724.8M675.5M577.5M397.2M377.6M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-1.78M-565.8K-3.57M-3.29M-2.44M-3.41M-3.08M-1.50M-1.84M-2.83M
Capital spending-4-3.07K-4-50-5.72K-5.72K-40.9K-40.9K-5.50K
Free cash flow-1.78M-568.9K-3.57M-3.29M-2.44M-3.41M-3.08M-1.54M-1.84M-2.84M
Cash from investing111.5K-3.07K000-5.72K-5.72K-52.9K-52.9K-11.9K
Cash from financing2.29M1.11M-22.6K5.53M-33.2K-37.0K5.00M5.75M1.40M1.41M
Dividends paid-5.11M-4.73M0
Share buybacks-236.6K1.28M19.8K-427.8K-427.8K0-275.4K-291.7K-255.5K-163.6K
Change in cash622.2K538.5K-3.59M2.24M-2.47M-3.45M1.92M4.20M-444.4K-1.43M

Open Financials

Filings

FilingDateTypeFiled with
Executive Director CEO Commences - Appendix 3XNov 8, 2026Management or board changeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 27, 2026Quarterly reportASX
Biotron Receives Additional $208,463 Tax RefundOct 22, 2026ResultsASX
Annual Report/Notice of AGM/Proxy FormOct 22, 2026Meeting noticeASX
Director Appointment Michael Thurn & Appendix 3XOct 18, 2026Management or board changeASX
Appointment of CEO and Executive DirectorOct 13, 2026Management or board changeASX
Resignation of Managing Director and Appendix 3ZSep 13, 2026Management or board changeASX
Change of Share RegistrySep 3, 2026Other filingsASX
Investor PresentationSep 2, 2026Other filingsASX
Appendix 4GAug 26, 2026Other filingsASX
All 98 filings
FilingDateTypeFiled with
Corporate Governance StatementAug 26, 2026Annual reportASX
Full Year Statutory Accounts and Appendix 4EAug 26, 2026Annual reportASX
Change in substantial holdingAug 17, 2026Ownership change noticeASX
HBV Treatment to Progress Towards Human TrialsAug 16, 2026Other filingsASX
Sedarex First Milestone MetJul 12, 2026Other filingsASX
$525K R&D Rebate ReceivedJun 3, 2026ResultsASX
Hepatitis B Virus Program UpdateMar 17, 2026Other filingsASX
Half Yearly Report and AccountsFeb 26, 2026Interim reportASX
Successful Issue of the Entitlement Offer ShortfallJan 29, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 28, 2026Quarterly reportASX
Security Class Reinstatement to Quotation - BITODec 21, 2025Trading halt or suspensionASX
Rights Issue CloseDec 19, 2025FinancingASX
Security Class Suspension from Quotation - BITODec 14, 2025Trading halt or suspensionASX
Non-Renounceable rights Issue ProspectusNov 18, 2025Offer documentASX
Acquisition of Sedarex Limited and $2.5m capital raisingOct 15, 2025Acquisition or disposalASX
Trading HaltOct 12, 2025Trading halt or suspensionASX
Pause in TradingOct 12, 2025Trading halt or suspensionASX
Full Year Statutory Accounts and Appendix 4EAug 27, 2025Annual reportASX
Rights Issue ClosedApr 7, 2025FinancingASX
Replacement ProspectusMar 12, 2025Offer documentASX
Response to ASX Query LetterMar 12, 2025Explanation requestASX
Supplementary ProspectusMar 4, 2025Offer documentASX
Response to ASX Aware QueryMar 3, 2025Explanation requestASX
ProspectusMar 2, 2025Offer documentASX
Renounceable Rights IssueFeb 27, 2025FinancingASX
Updated Appendix 4CFeb 3, 2025Quarterly reportASX
Agreement with C14 Consulting GroupNov 26, 2024Other filingsASX
$1.8M R&D Rebate ReceivedOct 13, 2024Other filingsASX
BIT225-012 PHASE 2 COVID-19 CLINICAL TRIALSep 5, 2024Other filingsASX
BIT225 Phase 2 HIV Efficacy Trial Meets Primary ObjectivesJun 19, 2024Other filingsASX
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIVApr 4, 2024Other filingsASX
Response to ASX Price QueryMar 26, 2024Explanation requestASX
COMPLETION OF PHASE 2 COVID CLINICAL TRIALAug 16, 2023Other filingsASX
Second Site Approved for Phase 2 Covid-19 TrialMay 12, 2023Other filingsASX
Commencement Phase 2 Covid-19 Clinical TrialMay 3, 2023Other filingsASX
Completion of Phase 2 HIV-1 Clinical TrialsMar 8, 2023Other filingsASX
International Presentation of BIT225 COVID-19 DataFeb 20, 2023Other filingsASX
$1.43M R&D rebate receivedNov 18, 2022Other filingsASX
Commencement of Rights Trading - BITRCOct 31, 2022Other filingsASX
Renounceable IssueOct 26, 2022Other filingsASX
Second BIT225 Phase 2 HIV-1 Clinical Trial Fully RecruitedOct 3, 2022Other filingsASX
Bit225 Covid-19 Human Study CommencedSep 13, 2022Other filingsASX
BIT225 Phase 2 HIV-1 Clinical Trial Fully RecruitedAug 23, 2022Other filingsASX
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAMMay 30, 2022GuidanceASX
BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALSMay 2, 2022Other filingsASX
Quarterly Cash Flow Report Appendix 4CApr 26, 2022Quarterly reportASX
Quarterly Activities ReportApr 26, 2022Quarterly reportASX
$1.56M R&D Rebate ReceivedApr 5, 2022Other filingsASX
BIT225 Effectiveness Against COVID-19 in AnimalsMar 17, 2022Other filingsASX
Quarterly Appendix 4C Cash Flow ReportJan 27, 2022Quarterly reportASX
BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALSNov 24, 2021Other filingsASX
COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALSNov 1, 2021Other filingsASX
Quarterly Cash Flow ReportOct 27, 2021Quarterly reportASX
Full Year Statutory Accounts and Preliminary Final ReportAug 27, 2021Annual reportASX
$1.4M R&D Tax RebateApr 28, 2021Other filingsASX
Appendix 4C - quarterlyApr 28, 2021Quarterly reportASX
Quarterly Cashflow ReportJan 28, 2021Quarterly reportASX
Biotron Compounds Show Activity Against SARS-CoV-2 VirusSep 6, 2020Other filingsASX
Full Year Statutory AccountsAug 27, 2020Annual reportASX
BIT225 Reverses HIV-Induced Immune EvasionJul 6, 2020Other filingsASX
R&D Tax Refund ReceivedMar 18, 2020Other filingsASX
BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONSMar 11, 2020Other filingsASX
Biotron to Test its Compounds Against CoronavirusFeb 5, 2020Other filingsASX
Biotron Secures $5.1 Million Underwriting AgreementNov 8, 2019Other filingsASX
Presentation to InvestorsOct 31, 2019Other filingsASX
Appointment of International Advisory Board for BIT225Oct 1, 2019Other filingsASX
Presentation at BIO 2019Jun 7, 2019Other filingsASX
PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATANov 28, 2018Other filingsASX
Response to ASX aware letterOct 30, 2018Explanation requestASX
Biotron Secures $4.7 Million Underwriting AgreementOct 16, 2018Other filingsASX
$1.07 million R&D Tax Incentive ReceivedOct 14, 2018Other filingsASX
Significant Immunological Outcomes in BIT225 HIV-1 TrialSep 28, 2018Other filingsASX
Update on Progress of BIT225 Phase 2 HIV-1 Clinical TrialAug 7, 2018Other filingsASX
Response to ASX Appendix 4C QueryMay 10, 2018Explanation requestASX
Biotron Compounds Demonstrate Activity Against HBVNov 15, 2017Other filingsASX
$1.6 Million R&D Tax Incentive ReceivedNov 1, 2017Other filingsASX
BIT225 Phase 2 HIV-1 Clinical Trial UpdateJun 15, 2017Other filingsASX
$1.6 Million R&D Tax Rebate ReceivedFeb 12, 2017Other filingsASX
BIT225 Accelerates HIV-1 Virus ReductionFeb 6, 2017Other filingsASX
Zika Virus Program UpdateAug 22, 2016Other filingsASX
Biotron compounds demonstrate activity against Zika virusMay 23, 2016Other filingsASX
$1.5 Million R&D Tax RebateApr 20, 2016Other filingsASX
Trading haltMar 30, 2016Trading halt or suspensionASX
Phase 2 Hepatitis C Trial SuccessMar 17, 2016Other filingsASX
BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTIONFeb 18, 2016Other filingsASX
BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUSFeb 16, 2016Other filingsASX
INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDYFeb 11, 2016Other filingsASX
Annual Report to ShareholdersFeb 10, 2016Annual reportASX

Open Filings

Cap table

Built by 6ix from Biotron Limited’s releases

Common shares
2,785,204,977
Fully diluted
2,785,204,977

Fully diluted

LineShares
Common shares2,785,204,977

Share count over time

CountShares
Nov 22, 20262,785,204,977

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Graeme WaldIndependent and Non-Executive Director · Since at least Nov 5, 2026
Marcelo MoraCompany Secretary · Since at least Nov 5, 2026
Michael J. ThurnIndependent and Non-Executive Director · Since at least Nov 5, 2026
Michael MedwayIndependent and Non-Executive Director · Since at least Nov 5, 2026
Paul KasianIndependent and Non-Executive Chairman · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Biotron Limited.